N-(α'-hydroxy-α-oxo-bibenzyl-4-yl)-acetamide | 101283-78-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: N-(α'-hydroxy-α-oxo-bibenzyl-4-yl)-acetamide
• 英文别名: N-(α'-Hydroxy-α-oxo-bibenzyl-4-yl)-acetamid；4-Acetamino-benzoin；N-[4-(2-hydroxy-2-phenylacetyl)phenyl]acetamide
• CAS: 101283-78-7
• 化学式: C₁₆H₁₅NO₃
• 分子量: 269.3
• InChiKey: FWDIJKLHVPTLAH-UHFFFAOYSA-N

物化性质

• 熔点：
  157 °C(Solv: water (7732-18-5))
• 沸点：
  530.9±40.0 °C(Predicted)
• 密度：
  1.264±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(α'-hydroxy-α-oxo-bibenzyl-4-yl)-acetamide 在 吡啶 、 copper(II) sulfate 作用下， 生成 N-[4-(2-氧代-2-苯基乙酰基)苯基]乙酰胺
  参考文献：
  名称：

  Merz; Plauth, Chemische Berichte, 1957, vol. 90, p. 1744,1756

  摘要：

  DOI：
• 作为产物：
  描述：

  对乙酰氨基苯甲醛 、 苯甲醛 在 potassium cyanide 、 乙醇 作用下， 生成 N-(α'-hydroxy-α-oxo-bibenzyl-4-yl)-acetamide
  参考文献：
  名称：

  Merz; Plauth, Chemische Berichte, 1957, vol. 90, p. 1744,1756

  摘要：

  DOI：

文献信息

• [EN] USP7 BINDING SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES & USES THEREOF<br/>[FR] MOLÉCULES CHIMÉRIQUES CIBLANT LA SURVIE (SURTAC) SE LIANT À USP7 ET LEURS UTILISATIONS
  申请人：LOCKI THERAPEUTICS LTD

  公开号：WO2022148821A1

  公开（公告）日：2022-07-14

  Chimeric molecules that include a USP7 binding domain and uses thereof for deubiquitinating a ubiquitinylated protein, and or for treating a disease in a subject in need are provided herein. Further, Survival-Targeting Chimeric (SURTAC) molecules that include a USP7 binding domain linked to a target protein binding domain are disclosed herein, as are their uses for deubiquitination and treating disease. In some instances, the target protein is a ubiquitinylated protein, wherein a bound USP7 enzyme may proteolytically remove ubiquitin from the target ubiquitinylated protein.

  本文提供了包含USP7结合域的嵌合分子及其用途，用于去泛素化泛素化蛋白质或治疗需要的主体的疾病。此外，本文还公开了包括USP7结合域连接到目标蛋白质结合域的Survival-TArgeting Chimeric（SURTAC）分子及其用途，用于去泛素化和治疗疾病。在某些情况下，目标蛋白质是泛素化蛋白质，其中结合的USP7酶可以通过蛋白酶作用从目标泛素化蛋白质中去除泛素。
• [EN] USP5 BINDING SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES & USES THEREOF<br/>[FR] MOLÉCULES CHIMÉRIQUES VISANT LA SURVIE ET SE LIANT À USP5 (SURTAC) ET LEURS UTILISATIONS
  申请人：LOCKI THERAPEUTICS LTD

  公开号：WO2022148822A1

  公开（公告）日：2022-07-14

  Chimeric molecules that include a USP5 binding domain and uses thereof for deubiquitinating a ubiquitinylated protein, and or for treating a disease in a subject in need are provided herein. Further, Survival-Targeting Chimeric (SURTAC) molecules that include a USP5 binding domain linked to a target protein binding domain are disclosed herein, as are their uses for deubiquitination and treating disease. In some instances, the target protein is a ubiquitinylated protein, wherein a bound USP5 enzyme may proteolytically remove ubiquitin from the target ubiquitinylated protein.

  本文提供了包括USP5结合域的嵌合分子，以及其用于去泛素化泛素化蛋白质或治疗需要治疗的主体的用途。此外，本文还披露了包括USP5结合域连接到目标蛋白质结合域的Survival-TArgeting Chimeric（SURTAC）分子，以及它们用于去泛素化和治疗疾病的用途。在某些情况下，目标蛋白质是泛素化蛋白质，其中结合的USP5酶可以蛋白水解地从目标泛素化蛋白质中去除泛素。
• SALTS OF CONJUGATES FOR CANCER THERAPY
  申请人：BioSight Ltd.

  公开号：EP3383883A1

  公开（公告）日：2018-10-10
• ISOLATED INTESTINAL MUCOSA AND USES THEREOF
  申请人：LI Albert

  公开号：US20190293634A1

  公开（公告）日：2019-09-26

  The present disclosure provides an in vitro reagent for evaluating xenobiotic metabolism in a cell culture based assay. The in vitro reagent is an admixture of a cell culture medium and isolated intestinal mucosa comprising villi wherein the intestinal mucosa was eluted from a lumen of the intestine. The isolated mucosa comprises metabolically competent cells. Addition of a xenobiotic test compound to the in vitro reagent allows metabolism of the test compound by the isolated intestinal mucosa comprising villi.
• [EN] SALTS OF CONJUGATES FOR CANCER THERAPY<br/>[FR] SELS DE CONJUGUÉS EN CANCÉRO-THÉRAPIE
  申请人：BIOSIGHT LTD

  公开号：WO2017094011A1

  公开（公告）日：2017-06-08

  The present invention relates to pharmaceutically acceptable salts of conjugates comprising a chemotherapeutic drug and an amino acid or a derivative thereof, which are readily taken up by a target cell and reduce side effects induced by the chemotherapeutic drug. In particular, the present invention relates to pharmaceutically acceptable salts of conjugates comprising cytidine analog drugs and aspartic or glutamic acid and analogs thereof, pharmaceutical compositions comprising these conjugates and use thereof for the treatment of cancer or a pre-cancer condition or disorder.